Innovation Pharmaceuticals Inc (IPIX)

[BeingReal]

I believe the answer to your question has been glossed over by this board. During the interview, Dr. B provided a clue to his overall strategy in answering a question about Kevetrin. I believe the same strategy holds true for Brilacidin. Consider what Dr. B. said here:

"Further, we believe that it will be an anchor if we can demonstrate that the response in rodents is mirrored in treatment of patients.

To accomplish this, we are doing studies in the lab in animal models of ovarian cancer aimed at demonstrating the effect of Kevetrin TM activation of p53 to treat the disease. This strategy should enable us to further anchor the effect of Kevetrin TM in the Phase 2 trial as it relates to key biologic measures. In my opinion, many companies make a mistake by prematurely jumping to a long-term endpoint such as progression-free survival, before proof of concept is firmly established. It is a compelling story to tell if you can see the effect of a compound in an animal model replicated in human studies."

In addition, with the immune system, we know that the immune response, which includes how our system attacks a foreign element and the resulting inflammatory outcome, it makes sense to learn as much as we can about our drug in B-UP and B-OM in a cost and time efficient way. The results of these trials will clearly provide insights to how B works and confirm how to proceed. IMO.